|
Volumn 94, Issue 3, 2015, Pages 279-280
|
Corrigendum to: Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia (European Journal of Haematology, (2015), 94, 3, (279-280), 10.1111/ejh.12454);Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HISTAMINE;
INTERLEUKIN 2;
ACUTE GRANULOCYTIC LEUKEMIA;
ALLOTRANSPLANTATION;
CANCER IMMUNOTHERAPY;
COMPARATIVE STUDY;
CONSOLIDATION CHEMOTHERAPY;
DISEASE FREE SURVIVAL;
HUMAN;
LETTER;
LEUKEMIA RELAPSE;
LOW DRUG DOSE;
LYMPHOCYTE;
LYMPHOCYTE COUNT;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT OUTCOME;
ACUTE MYELOBLASTIC LEUKEMIA;
BLOOD;
FEMALE;
MALE;
PATHOLOGY;
FEMALE;
HUMANS;
LEUKEMIA, MYELOID, ACUTE;
LYMPHOCYTE COUNT;
MALE;
|
EID: 84923266510
PISSN: 09024441
EISSN: 16000609
Source Type: Journal
DOI: 10.1111/ejh.13181 Document Type: Erratum |
Times cited : (4)
|
References (4)
|